Critical Business Issues and Strategies for ASCs Resulting From COVID-19

Overview


The Coronavirus (COVID-19) pandemic continues to cause substantial disruption to the ambulatory surgery center (ASC) industry. The path back to normalcy is uncertain, as we wait to see how long the pandemic and its effects will last. On the positive side, there are now discussions of a state-by-state phased plan to start re-opening the economy. We understand that the first phase in most states includes allowing elective outpatient surgical procedures to resume.

The timing is ripe to hear from experienced ASC CEOs who will share their successful COVID-19 strategies, as well as their vision and plans for the future. In this in-depth virtual conference, we will also address ASC M&A activity, which has been at a practical standstill, and map out strategies and the vision of ASC M&A executives for the post-COVID-19 ASC deal market.

For inquiries, please contact Hillary Hitt.

Registration Information

TIME

12:00 pm – 1:15 pm (EDT)

Agenda


CEO Panel: The Current State and Future of the ASC Industry
In the face of COVID-19 and its tremendous impact on the ASC industry, ASC management companies have been forced to act quickly, while being thoughtful about the future. In this session, CEOs of leading ASC management companies will share their strategies for dealing with and surviving COVID-19, as well as their insights regarding the ASC industry post-pandemic, including their expected plans for reopening centers and anticipated lingering effects to the industry.

Critical Regulatory Update
We will briefly cover the latest regulatory developments which have a specific impact on the ASC industry, including access to government subsidies, loans, grants, and tax relief applicable to ASCs. Also, we’ll cover the latest on the phased in allowance of elective surgical procedures.

ASC Transactions Panel: An Era of Uncertainty
ASC M&A transactions have been impacted by COVID-19. How have ASC M&A executives handled transactions that were pending or going to market when COVID-19 hit? Importantly, when we emerge from this crisis, will ASC transactional activity resume to pre-COVID-19 volume? Will physicians have the appetite to do deals? This chief development officer and investment banking panel will provide insights into these and other questions.